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Abstract B-cell translocation gene 3 (BTG3) is a member of
the BTG family which inhibits cell proliferation, metastasis,
and angiogenesis, and also regulates cell-cycle progression
and differentiation in a variety of cell types. However, there
is no study to analyze BTG3 expression in epithelial ovarian
carcinoma (EOC). Here, we investigated the expression of
BTG3 in EOC carcinogenesis and subsequent progression.
BTG3 mRNA expression was detected by real-time RT–
PCR in ovarian benign and malignant tumors. The expression
of BTG3 protein was examined by immunohistochemistry on
tissue microarrays containing ovarian normal tissue, benign
and borderline epithelial ovarian tumors, and EOCs.
Relationships of BTG3 with both EOC clinicopathology and
prognosis were analyzed statistically. The expression of
BTG3 protein was also evaluated in ovarian normal tissue,
benign tumors, and EOCs by western blot. The BTG3 mRNA
expression level was higher in ovarian normal tissue and
benign tumors than that in borderline, primary, and metastatic
carcinoma (p<0.05), and was negatively correlated with de-
differentiation and FIGO staging of EOC (p<0.05). Using
western blot, BTG3 protein was found lower in EOCs com-
pared to the normal and benign tumors (p<0.05), and poorly
differentiated EOCs showed lower BTG3 expression than
well-differentiated and moderately differentiated EOCs
(p<0.05). Immunohistochemically, BTG3 protein expression
was statistically lower in EOCs than normal tissue and benign
tumors (p<0.05). EOC patients with low BTG3 protein ex-
pression showed a higher incidence of metastasis (p=0.020),
poor differentiation (p=0.030), and shorter disease-free time
and overall survival time (p<0.05). By using Cox’s propor-
tional hazard model, BTG3 protein expression and FIGO
staging were independent prognostic factors for both
disease-free time and overall survival time of EOCs
(p<0.05). It was suggested that down-regulated BTG3 expres-
sion might play roles in the pathogenesis and aggressiveness
of EOC. BTG3 protein expression may be considered as a
good marker to indicate the favorable prognosis of EOCs.
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Introduction
Ovarian cancer is the second leading cancer in women and the
fifth leading cause of cancer-related deaths in women.
Epithelial ovarian carcinoma (EOC) is disproportionately
deadly because no sophisticated approach for the early diag-
nosis makes most ovarian cancers diagnosed at advanced
stages [1]. Treatment may be shortly effective; patients with
advanced International Federation of Gynecology and
Obstetrics (FIGO) stages still have poor prognosis with 5-
year survival rates below 33 % depending on response to
chemotherapy [2]. EOCs are believed to arise from the ovarian
epithelium and fallopian tubes, probably due to such risk
factors as hereditary, reproductive, hormonal, inflammatory,
hereditary, and geographic factors [3]. Carcinogenesis and
progression of ovarian carcinoma are multistage processes,
and increased understanding of the changes that occur in gene
expression during carcinogenesis may result in the
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improvement of its diagnosis, treatment, and prevention.
Therefore, it is an urgent need to identify more effective and
new molecular targeted therapies for EOC.
The human BTG (B-cell translocation gene)/Transducer of
ErbB2 gene family comprises of six proteins (BTG1,
BTG2/TIS21/PC3, BTG3, BTG4/PC3B, Transducer of
ErbB-2, and TOB2), which inhibit cell proliferation and reg-
ulate cell-cycle progression and differentiation in a variety of
cell types. BTG is a nuclear protein that is imported into the
nucleus through a nuclear localization signal (NLS)-mediated
mechanism, and its nucleocytoplasmic translocation depends
on cell growth states [4]. The conserved N-terminal BTG
domain encompasses 104–106 amino acids and contains
Box A and B. It has been reported that the conserved BTG
domain mediates interactions with the highly similar Caf1a
(CNOT7) and Caf1b (CNOT8) catalytic subunits of the Ccr4–
Not deadenylase complex, which was closely associated with
the anti-proliferative activity of BTG/TOB proteins.
Furthermore, the activity of BTG/TOB proteins in the regula-
tion of mRNA abundance and translation is dependent on
Caf1a/Caf1b [5]. BTG3/ANA/APRO4 (MGC8928, Protein
BTG3, Protein Tob5, TOB5, tob55, TOB55, TOFAD) is a
member of the anti-proliferative BTG family and has been
reported to be a tumor suppressor gene in some malignancies
[6]. The human BTG3 gene is localized in chromosome
21q21.1, and its two cDNAvariants encode two variants with
132-nucleotide deletion by alternative splicing [7–9]. BTG3 is
a downstream target of p53 and interacts with E2F1 to sup-
press the DNA binding of the E2F1–DP1 transcription factor
complex through an N-terminal domain including the con-
served Box A, suggesting its negative regulatory influence on
cellular S-phase progression [10]. BTG3 is also able to inter-
act with the Smad8 receptor-regulated Smad transcription
factor as BTG1 and BTG2 [11]. BTG3 associates with Src
via its C-terminal proline-rich domain to down-regulate Src
tyrosine kinase activity and suppresses Ras/MAP kinase sig-
naling. BTG3 deficiency enhances bone morphogenetic
protein-induced ectopic bone formation via transcriptional
events [12]. BTG3 can associate with Caf1 and is a preferred
partner of the CCR4 transcription factor-associated protein
Caf1 by its amino-terminal half [13]. Loss of BTG3 in normal
cells induced cellular senescence, which was correlated with
enhanced ERK-AP1 signaling and elevated expression of the
histone H3K27me3 demethylase JMJD3/KDM6B, leading to
acute induction of p16(INK4a) [14].
In mice, BTG3mRNAwas ubiquitously expressed in adult
mice, the level being relatively high in the heart, lung, kidney,
and testis, but low in the spleen and skeletal muscle. In human,
BTG3 expression is down-regulated in lung, prostate, or renal
cancer tissues and cells, and induced by genistein and 5-aza-
2′-deoxycytidine, suggesting silenced BTG3 expression is
attributable to its epigenetic methylation [8, 15–17]. Long-
term observation of BTG3-deficient mice reveals that 8 % of
them develop lung tumors (5/66) by 21 months after birth.
Exogenous BTG3 protein suppresses the levels of matrix
metalloproteinase-2 and plasminogen activator inhibitor-1 ex-
pression in lung cancer cells [15]. Taken together, it is
suggested that BTG3 protein might have a negative regulatory
effect on tumor progression by suppressing angiogenesis,
invasion, and metastasis. In our previous work, aberrant
BTG3 expression was found to link to gastric carcinogenesis
and its venous invasion (unpublished). To explore the roles of
BTG3 expression in the ovarian carcinogenesis and subse-
quent progression, we examined the expression of BTG3
mRNA and protein in ovarian normal, benign, and borderline
tumor, primary, and metastatic epithelial ovarian carcinoma in
omentum, and compared them with clinicopathological pa-
rameters of EOCs.
Materials and methods
Tissue samples Between January 2005 and December 2011,
ovarian normal tissue, benign and borderline epithelial ovar-
ian tumors (serous and mucinous types were included), pri-
mary epithelial ovarian carcinoma, and omentum with
metastatic tumor were collected from surgical resection at
the Department of Gynecology, The First Hospital Affiliated
to China Medical University. The average age at surgery was
51.6 years (range 20–81 years). The parts of ovarian tissues
were subjected to the routine preparation of pathological
block. Some samples were frozen immediately in liquid nitro-
gen and stored at −80 °C until use. None of the patients
underwent chemotherapy, radiotherapy, or adjuvant treatment
before surgery. We followed up the patients by consulting
their case documents and by telephone. Informed consents
were obtained from all subjects, and the study was approved
by the China Medical University Ethics Committee.
Pathology All tissues were fixed in 10 % neutral formalin,
embedded in paraffin, and sections cut at 4 μm. These
sections were stained by hematoxylin and eosin (HE) to
confirm their histological diagnosis and other microscopic
characteristics. The staging for each ovarian carcinoma was
evaluated according to the International Federation of
Gynecology and Obstetrics (FIGO) staging system for the
extent of tumor spread. Histological architecture of ovarian
carcinoma was expressed in terms of WHO classification.
Real-time RT–PCR Total RNA was extracted from ovarian
tissues using QIAGEN RNeasy mini kit (QIAGEN,
Germany). Two micrograms of total RNA was subjected to
cDNA synthesis using the AMV transcriptase and random
primers (Takara, Otsu, Japan). Oligonucleotide primers for
PCR were sense, 5′-TGAAGTTA GATGGGCCAAAC-3′,
and anti-sense, 5′-CCAACAGAGTTGATGCACAA-3′, for
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BTG3 (NM_001130914.1, 1243–1425, 183 bp); and sense,
5′-CAATGACCCCTTCATTGACC-3′, and anti-sense, 5′-
TGGAAG ATGGTGATGGGATT-3′, for GAPDH (135 bp,
201–335, NM_002046.3). PCR amplification of cDNAwas
performed in 20-μl mixtures according to the protocol of
SYBR Premix Ex TaqTM II kit (Takara).
Western blot Frozen tissues were washed twice with ice-
cold PBS and homogenized on ice in 10 vol (w/v) of lysis
buffer containing 20 mM Tris–HCl, 1 mM EDTA, 50 mM
NaF, 50 mM NaCl, 1 mM Na3VO4, 1 % Triton X-100, and
1 mM PMSF. The homogenate was centrifuged at
15,000 rpm for 30 min at 4 °C. The supernatant was col-
lected and stored at −70 °C. Protein content was determined
using the BCA assay (Beyotime Institute of Biotechnology,
Jiangsu, China). Protein was separated by 10 % SDS–PAGE
and then transferred to PVDF blotting membranes, which
were then blocked for 2 h in 5 % milk in Tris-buffered saline
containing Tween-20 (TBST—10 mM Tris–HCl, 150 mM
NaCl, and 0.1 % Tween-20). For immunoblotting, the mem-
brane was incubated at 4 °C overnight with rabbit antibody
against BTG3 (1:1,000) from Sigma (HPA018400; Sigma,
USA) and mouse anti-β-actin antibody (1:1,000; Keygen
Biotech, Nanjing, China). Then, it was rinsed with TBST
three times and incubated with horseradish peroxidase con-
jugated anti-rabbit or anti-mouse IgG antibodies (1:2,000;
Zhongshan Golden Bridge Biotechnology, Beijing, China)
for 2 h. The Imaging System (DNR Bio-Imaging Systems,
Israel) was used for image capture. The optical density (OD)
of each band was measured using Image J software. The
BTG3 and β-actin OD ratio was calculated as relative
content and expressed graphically for the ovarian samples.
Tissue microarray Representative areas of solid tumors were
identified in HE-stained sections of the selected tumor cases
and a 2-mm-diameter tissue core per donor block was
punched out and transferred to a recipient block with a max-
imum of 48 cores using a Tissue Microarrayer (AZUMAYA
KIN-1, Japan). Four-micrometer-thick sections were consec-
utively incised from the recipient block and transferred to
poly-L-lysine-coated glass slides. HE staining was performed
on TMA for the confirmation of tumor tissue.
Immunohistochemistry Consecutive sections were depara
ffinized with xylene, rehydrated with alcohol, and subjected
to antigen retrieval by irradiating in target retrieval solution
(TRS; DAKO, USA) for 15 min with a microwave oven.
The sections were quenched with 3 % hydrogen peroxide in
absolute methanol for 20 min to block endogenous peroxi-
dase activity. Five percent bovine serum albumin was then
applied for 5 min to prevent non-specific binding. The
sections were incubated with the rabbit antibody against
human BTG3 (1:100) from Sigma, anti-Ki-67 (DAKO,
1:50) for 15 min, then treated with the anti-rabbit conjugated
to horseradish peroxidase (DAKO, USA; 1:00) antibodies
for 15 min. All the incubations were performed in a micro-
wave oven to allow intermittent irradiation as described
previously [18]. After each treatment, the slides were
washed with TBST three times for 1 min. Binding sites
were visualized with 3, 3′-diaminobenzidine. After
counterstained with Mayer’s hematoxylin, the sections were
dehydrated, cleared, and mounted. Omission of the primary
antibody was used as a negative control.
One hundred cells were randomly selected and counted
from five representative fields of each section blindly by two
independent observers (Deng BYand Zheng HC). The incon-
sistent data were confirmed by both persons until final agree-
ments were reached. The expression positivity was graded and
counted as follows: 0=negative, 1=1–49%, 2=50–74 %, and
3 ≥75 %. The staining intensity score was graded as follows:
1=weak, 2=intermediate, and 3=strong. The scores for
BTG3 positivity and staining intensity were multiplied to
obtain a final score, which determines their expression
as −=0, +=1–2, ++=3–4, and +++=6–9. The expression
positivity of Ki-67 was graded and counted as follows:
0 = negative, 1=1–49 %, 2=50–74 %, and 3 ≥75 %.
Measurement of CA125 Serum CA125 was determined by
Quantitative Chemiluminescence Immunoassay Kit
(Gentaur, France). Briefly, 50 μl of standard (0–1,000
U/ml), specimens, and controls were dispensed into appro-
priate wells. Then, we added 100 μl of Enzyme Conjugate
Reagent into each well, gently mixed, and incubated the
plate at room temperature for 60 min. The microtiter wells
were rinsed and flicked with wash buffer. After that, residual
water droplets were removed by striking the well sharply
onto absorbent paper. Finally, 100 μl Chemiluminescence
substrate solution into each well was dispensed, mixed
gently, and subjected to absorbance determination.
Statistical analysis Statistical evaluation was performed
using Spearman’s correlation test to analyze the rank
data and Wilcoxon’s test to differentiate the means of
different groups. Kaplan–Meier survival plots were gen-
erated and comparisons between survival curves were
made with log-rank test. Cox’s proportional hazards
model was employed for multivariate analysis. SPSS 10.0
software was applied to analyze all data, and p <0.05 was
considered statistically significant.
Results
The correlation of BTG3 mRNA expression with tumorigenesis
and clinicopathological features of ovarian carcinoma Wemea-
sured the expression of BTG3 mRNA in ovarian normal
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tissue (n=17), benign tumor (n=12), borderline tumor
(n=6), and primary (n=65) and metastatic carcinoma
(n=21) by real-time RT–PCR. As shown in Fig. 1, BTG3
mRNA expression level was higher in ovarian normal tissue
and benign tumor, and lower in borderline tumor and
primary and metastatic carcinoma (p<0.05, Fig. 1a, b).
Well-differentiated carcinoma showed higher BTG3
mRNA expression in comparison with moderately and
poorly differentiated ones (p<0.05, Fig. 1c). BTG3
mRNA displayed lower expression in advanced EOCs
(FIGO III and IV) than FIGO I and II staging EOC
(p<0.05, Fig. 1d).
BTG3 protein expression during ovarian carcinogenesis
and its correlation with clinicopathological parameters
of ovarian carcinoma By western blot assays, we mea-
sured BTG3 protein expression in normal ovary tissues
(n=9), benign ovarian tumors (n=10), and EOCs (n=59).
BTG3 was lower in EOCs than in normal ovary tissues
(p=0.002) and benign ovarian tumors (p=0.046) (Fig. 2).
BTG3 was lower in poorly differentiated EOCs than well-
differentiated and moderately differentiated EOCs
(p=0.045) (Fig. 2b). As shown in Fig. 3, BTG3 protein
distributed in the cytoplasm of normal ovary tissue, ovarian
benign tumor, and EOCs. BTG3 expression was detectable
in normal ovary tissue (78.6 %, 22/28), benign tumor
(80.0 %, 12/15), borderline tumor (41.7 %, 10/24), carcino-
ma (51.0 %, 127/249), and metastatic carcinoma in omen-
tum (50.0 %, 24/48), respectively. According to its
frequency and density, BTG3 protein expression was
statistically lower in ovarian carcinoma than normal ovary
and benign tumor (p<0.05, Table 1). Its expression level
was lower in ovarian borderline tumors than normal tissue
(p<0.05, Table 1). As summarized in Table 2, BTG3 expres-
sion was lower in EOCs of advanced FIGO staging
(p=0.020), moderate or poor differentiation EOC (p=0.030),
and higher Ki-67 expression (p=0.042). BTG3 expression in
EOCs was not associated with the age of the patients, serum
CA125, or pathological classification (p>0.05).
Survival analysis Follow-up information was available
on 108 ovarian carcinoma patients for periods ranging
from 1 to 107 months (median=62.3 months). Survival
curves for EOC were stratified according to BTG3
expression (Fig. 4). By using the Kaplan–Meier method,
we indicated that both survival time and disease-free
time for patients were linked to BTG3 expression status
(overall survival time, p=0.020, Fig. 4a; disease-free
time, p=0.021, Fig. 4b). Multivariate analysis using
Cox’s proportional hazard model indicated that FIGO
staging and BTG3 protein expression (p<0.05) but not
the patient age, pathological classification, differentia-
tion residual lesion size, or serum CA125 level were
independent prognostic factors for overall survival of
EOC (p>0.05, Table 3). Further, the patient’s age,
FIGO staging, and BTG3 protein expression (p<0.05)
but not pathological classification, differentiation residual
lesion size, or serum CA125 level were independent
prognostic factors for disease-free ovarian carcinomas
(p>0.05, Table 4).
Fig. 1 The correlation of BTG3 mRNA expression with tumorigenesis
and aggressive features of ovarian carcinoma. Real-time RT–PCR was
employed to amplify BTG3 mRNA in 121 ovarian samples (a). BTG3
mRNA level was higher in ovarian normal tissue (No, n=17) and
benign tumor (Be, n=12) than that in borderline tumor (Bor, n=6),
primary carcinoma (Ca, n=65), or metastatic carcinoma in omentus
(Om, n=21) (p<0.05, b). No statistical differences were found between
ovarian normal tissue (No) and benign tumor (Be), or among borderline
tumor (Bor), primary carcinoma (Ca), or metastatic carcinoma in
omentus (Om). Well-differentiated carcinoma showed higher BTG3
mRNA expression in comparison with moderately and poorly differ-
entiated ones (p<0.05, c). BTG3 mRNA displayed lower expression in
advanced FIGO staging EOC (p<0.05, d)
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Discussion
Increasing evidence suggests that BTG3 is thought to be a
negative regulator of cellular S-phase progression, and it has
been shown that its anti-proliferative action is through inhi-
bition of transcription factor E2F1 or interaction with Smad
transcription factor as a tumor suppressor [10, 11]. Here, we
for the first time examined in situ BTG3 expression in
ovarian normal tissue, benign and borderline tumor, and
carcinoma samples. It was found that BTG3 protein was
mainly localized in the cytoplasm of ovarian fiber cells,
fallopian tube, benign and borderline tumor, and carcinoma
cells. It was suggested that the BTG3 expression pattern has
cellular specificity, which determines its biological functions.
However, the mechanisms of its cell-specific characteristics
should be further investigated.
Using western blot and immunochemistry staining, BTG3
expression was reduced in ovarian carcinoma, compared with
ovarian normal tissue and benign tumor, indicating that down-
regulated BTG3 expression contributes to ovarian epithelial
carcinogenesis. In the present study, BTG3 mRNA level was
reduced from ovarian borderline tumor and carcinoma, in line
with the immunohistochemical data. Yoneda et al. [15] also
reported that BTG3mRNA expression was down-regulated in
lung carcinoma tissue or cell lines, consistent with the normal
counterparts. Yu et al. [8] demonstrated that BTG3 expression
was markedly reduced and its promoter region of BTG3 was
hypermethylated without detectable mutations in the promoter
Fig. 2 The correlation of BTG3 protein expression with tumorigenesis
and aggressive features of ovarian carcinoma. Western blot was
employed to valuate BTG3 protein expression in 78 ovarian samples
(a). BTG3 was higher in ovarian normal tissue (n=9) and benign tumor
(n=10) than that in EOCs (n=59) (p<0.05, b). Well-differentiated and
moderately differentiated EOC showed higher BTG3 expression in
comparison with poorly differentiated ones (p=0.045, c). No statistical
difference of BTG3 expression was found between FIGO I/II and
FIGO III/IV staging (p>0.05, d)
Fig. 3 Immunohistochemical
staining of BTG3 protein in
ovarian samples. BTG3 protein
was positively detected in the
cytoplasm of ovarian fiber cells
(a), fallopian tube (b),
borderline serous tumor (c),
primary serous adenocarcinoma
(d, e), and metastatic serous
adenocarcinoma in omentus (f)
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and coding region in a wide variety of human breast cancer
cell lines, suggesting that hypermethylation might be an im-
portant mechanism for inactivation of BTG3. Methylation-
mediated down-regulation of BTG3 was also documented in
renal and prostate cancer cells [16, 17]. Sasajima et al. [19]
suggested that anti-proliferative proteins of the BTG/Tob fam-
ily might be degraded by the ubiquitin–proteasome system.
The ubiquitin-mediated degradation of BTG protein could
support the BTG3 hypoexpression in ovarian borderline tu-
mor and EOCs. However, the mechanism of BTG3 down-
regulation in EOC will be investigated in the future study.
In the present study, BTG3 protein expression was pos-
itively linked to clinicopathological features of ovarian
carcinoma, including differentiation and FIGO staging in
agreement with the data of our real-time RT–PCR, indicat-
ing that BTG3 might be involved in the development and
differentiation of EOC and be considered as a good bio-
marker to indicate the aggressive behaviors of EOC. We
also compared the expression of BTG3 and Ki-67 in EOC
samples. Ki-67 is a nuclear protein found in G1 phase of cell
cycle associated with cell proliferation. As an excellent
marker to determine the cell proliferation index, Ki-67 was
also associated with EOC progression and prognosis [20].
Since increased Ki-67 expression revealed an increase in
mitotic cell activity and proliferation, the negative correla-
tion we found between BTG3 and Ki-67 expression
Table 1 BTG3 expression in
ovarian carcinogenesis
*p<0.05, compared with ovarian
normal tissue; **p<0.05, com-
pared with benign tumors
Groups n BTG3 expression
− + ++ +++ p value
Normal ovary 28 6 4 5 13
Ovarian benign tumor 15 3 1 4 7
Ovarian borderline tumor 24 14 4 2 4 0.037*
Ovarian carcinoma 249 122 44 50 33 0.008*
0.022**
Metastatic carcinoma in omentus 48 24 12 8 4 0.002*
0.001**
Table 2 The relationship be-
tween BTG3 expression and
clinicopathological features of
ovarian carcinomas
Clinicopathological features n BTG3 expression
− + ++ +++ PR (%) p value
Age (years) 0.466
<56 123 61 25 24 13 47.2
≥56 126 61 19 26 20 54.8
Pathological classification 0.715
Serous adenocarcinoma 185 95 29 36 25 48.6
Mucinous adenocarcinoma 26 11 5 7 3 57.7
Miscellaneous subtypes 38 16 10 7 5 57.8
FIGO staging 0.020
I–II 93 34 18 28 13 63.4
III–IV 156 88 26 22 20 43.6
Differentiation 0.030
Well differentiated 60 19 17 16 8 68.3
Moderately differentiated 103 53 14 19 17 48.5
Poorly differentiated 86 50 13 15 8 41.9
Serum CA125 concentration (U/ml) 0.085
<500 45 20 3 12 10 44.4
≥500 54 26 16 9 3 51.9
Ki-67 expression 0.042
− 54 15 18 14 7 72.2
+ 38 25 7 3 3 34.2
++ 35 19 3 7 6 45.7
+++ 39 28 1 5 5 28.2
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provided evidence about the suppressive effects of BTG3 on
the cell proliferation. Regarding the prognostic significance
of other BTGs, Möllerström et al. [21] demonstrated high-
level BTG2 protein expression correlates with prolonged
survival in patients with breast carcinoma. Kamalakaran et
al. [22] identified differential methylation of CpG islands
proximal to BTG1 as having prognostic value independent
of subtypes and other clinical factors of luminal breast
cancers. We revealed the inverse links between BTG3 ex-
pression levels and the overall and disease-free survival of
patients with EOC in the present study. Multivariate analysis
demonstrated that BTG3 protein expression was an inde-
pendent factor to indicate the favorable prognosis of ovarian
carcinoma. Also in our study, FIGO staging was the inde-
pendent factor of both the overall and disease-free survival
of the EOC, as other researchers revealed [23, 24]. Since
Bast et al. [25] had developed an assay for serum CA125
and found it elevated in 82 % of EOC patients, serum
CA125 kinetics during chemotherapy had value in
predicting survival of EOCs. Some research also revealed
that pre-operative serum CA125 was an independent factor
to EOC prognosis [26]. But in our study, there is no statis-
tical relationship between pre-operative CA125 and progno-
sis of EOCs. This may be due to many characteristics which
could profoundly influence serum CA125, including tumor
characteristics such as histology, grade, stage, and presence
of ascites together with certain conditions such as peritoneal
and mucosal inflammation [27]. Our findings suggested that
BTG3 protein expression could be employed to indicate the
prognosis of ovarian carcinoma patients as an independent
factor.
In conclusion, our study indicated that BTG3 was down-
regulated in epithelial ovarian carcinoma, which might have
impact on the clinicopathogenesis of EOC, and should be
considered as a good biomarker for ovarian carcinogenesis
and subsequent progression. Nevertheless, the biological
functions of BTG3 in EOC need further investigation.
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